Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adding This to DIPSS Helps HCT Outcome Prediction

Biol Blood Marrow Transplant; ePub 2017 Sep 29; Bannow, et al

Adding cytogenetics, thrombocytopenia, and red cell transfusion dependence as risk factors appears to improve the Dynamic International Prognostic Scoring System (DIPSS), according to a study involving 233 individuals with myelofibrosis (MF). Investigators sought to determine if the enhanced system would predict post- hematopoietic cell transplantation (HCT) outcomes better than DIPSS-alone. Among the results:

  • 5-year overall survival rate for patients with low/int-1 risk MF was 78%.
  • Relapse and treatment-related mortality rates were 5% and 20%, respectively.
  • 5-year overall survival rate in patients with high-risk MF was 35%.
  • Relapse and treatment-related mortality rates were 28% and 40%, respectively.
  • HCT-comorbidity index of ≥3 was linked with higher non-relapse and overall mortality, and lower relapse-free survival.
  • Older patients were 3 times more likely to experience relapse.
  • At a median follow-up of 8 years, ~half of patients had survived.

The authors noted that the findings may help improve the ability to advise patients about transplant timing.

Citation:

Bannow B, Salit R, Storer B, et al. Hematopoietic cell transplantation for myelofibrosis: DIPSS plus risk predicts post-transplant outcomes. [Published online ahead of print September 29, 2017]. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2017.09.016.

This Week's Must Reads

Guideline on Platelet Transfusion in Ca Patients, J Clin Oncol; ePub 2017 Nov 28; Schiffer, et al

Encourage This Behavior in Childhood ALL Survivors, Cancer; ePub 2017 Dec 4; Howell, Wilson, et al

Adipokines, Swelling, & Adiposity in HCT Survivors, Biol Blood Marrow Transplant; ePub 2017 Nov 29; Ketterl, et al

Prognostic Testing Patterns, CLL Outcomes Assessed, Clin Lymphoma Myeloma Leuk; ePub 2017 Dec 5; Mato, et al

Outcomes Post-AlloSCT in DHL/DEL Lymphomas, Biol Blood Marrow Transplant; ePub 2017 Nov 28; Herrera, et al

Must Reads in Myelodysplastic Syndrome

Myeloma Precursor More Prevalent in Some Blacks, Blood Cancer J; ePub 2017 Oct 20; Landgren, et al

This Improves Survival After HLA-Haplo Transplant, Biol Blood Marrow Transplant; ePub 2017 Oct 18; McCurdy, et al

Adding This to DIPSS Helps HCT Outcome Prediction, Biol Blood Marrow Transplant; ePub 2017 Sep 29; Bannow, et al

Impact of Fluid Overload on HSCT Outcomes, Biol Blood Marrow Transplant; ePub 2017 Aug 24; Rondón, et al

Survival in Patients with Plasma Cell Myeloma, Leuk Lymphoma; ePub 2017 Jul 21; Santiago, et al